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Myotubesits that insulin resistant condition in type 2 diabetes is caused by defects at one or
several levels of the insulin-signaling cascade in skeletal muscles, adipose tissue and liver, that quantitatively
constitute the bulk of the insulin-responsive tissues. Hence, the gradual uncovering of the biochemical events
deﬁning the intracellular signaling of insulin has been quickly followed by clinical studies on humans
attempting to deﬁne the molecular defect(s) responsible for the establishment of the insulin resistant state.
While the existence of molecular defects within the insulin signal transduction machinery is undisputed,
contrasting data exist on what is the principal molecular alteration leading to insulin resistance. Such
discrepancies in the literature may depend on: 1) different subject characteristics, 2) methodological
differences 3) small cohorts of subjects, and – not least – 4) intrinsic limitations in studying every detail of the
insulin signaling cascade. Here, we review the studies on humans exploring the defects of the insulin signaling
cascade generated by insulin resistance and type 2 diabetes, focusing on muscle and adipose tissue – which
account for most of the glucose disposal capacity of the body – with focus on the unresolved discrepancies
present in the literature.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThedemonstration that insulin acts through thebinding toaplasma
membrane receptor, dating back from the early '70s, suggested that the
altered sensitivity to insulin as observed in obesity, insulin resistance
and type 2 diabetes could be dependent on a diminished receptor level
or weak afﬁnity towards its agonist [1]. Since then, the intracellular
signalingmachinery relaying themetabolic actions of insulin has been
elucidated to a good extent, and several of the enzymes taking part in
insulin action have been shown to undergo alterations of their
physiological function in the insulin resistant state. The discovery of
the intracellular steps of insulin signaling has paved the way to
intensive investigation aiming at understanding the molecularS, glycogen synthase; GSK-3,
Jun N-terminal kinase; MAPK,
target of rapamycin; PDK1,
omain, pleckstrin homology
in; PI3K, phosphoinositide 3-
; PKB, protein kinase B; SHP2,
and Disease Laboratory, Baker
d, Melbourne, Victoria 3004,
rola).
l rights reserved.mechanism responsible for the establishment of the insulin resistant
state, both on rodent models and in humans. In this review, we survey
the molecular events of the insulin signaling cascade that have been
amenable to clinical investigation in human subjects. The focus will be
on the current understanding of the molecular disturbances of the
insulin signaling cascade in muscle and adipose tissue.
1.1. The insulin signaling cascade, an overview
The action of insulin is initiated by binding to its cognate receptor
and activation of the receptor's intrinsic protein tyrosine kinase
activity, resulting in the phosphorylation of tyrosine residues located
in the cytoplasmic face [2]. The activated receptor, in turn, recruits and
phosphorylates a panel of substrate molecules. Among these, IRS1 and
IRS2 appear to be the adapter molecules playing a major role in the
coupling to the PI3K-PKB andMAPK downstream kinases [3]. Tyrosine
phosphorylated IRS1/2 recruit the heterodimeric p85/p110 PI3K at the
plasmamembrane, where it produces the lipid secondmessenger PIP3,
which in turn activates a serine/threonine phosphorylation cascade of
PH-domain containing proteins [4]. PIP3 targets include PDK1, the
serine/threonine protein kinase B (PKB)/Akt, and the atypical protein
kinases C ζ andλ isoforms [5,6]. Mechanistically, PDK1, PKB and aPKCs,
which all contain a PH-domain, are recruited at the plasmamembrane
by binding to PIP3; thereon, PDK1 phosphorylates PKB and aPKCs on a
Fig.1. Schematic depiction of the insulin regulated intracellular signal transduction cascade, reporting the signaling steps whose alterations have been studied in insulin resistant and
type 2 diabetic subjects.
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domain, causing their activation [7–9]. Major targets of activated PKB
are GSK-3 [10] and AS160 [11]. Upon PKB-mediated phosphorylation
on Ser9, GSK-3 is inactivated [10]. This inactivation, in parallel to
protein phosphatase-1 (PP1) activation, relieves the inhibitory phos-
phorylation of GS, which becomes activated and promotes glycogen
synthesis [12]. PKB also regulates the insulin-stimulated translocation
of the glucose transporter GLUT-4 at the plasma membrane, resulting
in increased glucose uptake. This pathway involves an inhibitory
phosphorylation of the RabGTPase activating protein AS160. Inhibition
of AS160 favours the GTP-loaded state of Rab and relieves an inhibitory
effect towards GLUT-4 translocation from intracellular compartments
to the plasma membrane [13]. In addition to the role of PKB in
controlling GLUT-4 translocation, aPKCs act in parallel to – or can even
be substitutive for – PKB (Fig. 1) [14].
On a parallel pathway, activated IRS1/2 recruit Grb2, which
associates to SOS and activates the Erk1/2 MAPK pathway [15]. The
p38 and JNK stress-activated kinases – whose activation is mainly
dependent on stress signals and inﬂammatory cytokines [16,17] – have
also been shown to be phosphorylated/activated in response to insulin
[18,19]; although the pathway leading to their activation has not yet
been fully elucidated. Overall, alterations of the activation status of the
proximal insulin signaling enzymes (IR, IRS1/2, PI3K), and down-
stream targets (PDK, PKB and its targets GSK-3 and AS160, aPKCs, and
MAPK-family protein kinases) have been studied in muscle and
adipose tissue from insulin resistant, obese and type 2 diabetic
subjects, and the underlying insulin resistance has been attributed to
defects in one or more steps of the insulin signaling cascade.
1.2. Methodologies to study insulin signaling in human skeletal muscle
and adipocytes
Skeletal muscle accounts for a large percentage of the whole body
glucose uptake [20] and is an important site for insulin resistance in
type 2 diabetes, as proved in a pioneering study by DeFronzo et al.
[21]. At the same time, interest was also drawn to the adipose tissue,
as it was shown that adipose tissue in type 2 diabetic subjects was
resistant to insulin with respect to glucose transport [22], and had a
decreased insulin receptor kinase activity [23].The standard method for assessing insulin sensitivity in human
volunteers is the euglycaemic hyperinsulinaemic clamp. The clamp
technique, with or without radioactive tracers, was developed almost
30 years ago [21,24]. This method consists in the infusion of glucose
and insulin and concomitant monitoring of insulin and glucose levels
over several hours, allowing evaluation of peripheral insulin sensitiv-
ity, and hepatic glucose production if the infused glucose is labelled
either with radioactive or stable isotopes. Additionally, this study
design can be accompanied by the obtention of muscle/adipose tissue
biopsies, taken before and after the clamp protocol, to study the
biochemical/physiological effects of insulin and glucose in the
peripheral tissues of the patients.
Investigations published so far on the alterations in insulin
signaling in insulin resistant and/or type 2 diabetic subjects included
clamp studies of 40 min [6], 2 h [25–27], 3 h [28–32], 4 h [33] and 5 h
[34]. Furthermore, insulin infusion rates employed in these studies
ranged from 40 to 300 mU m−2 min−1, a parameter that – together
with the time of clamp – might explain some of the discrepancies in
the literature. The importance of the insulin infusion rate used is
controversial, since Nolan et al. [35] reported a dose-dependent
difference in IR autophosphorylation between lean nondiabetic, obese
nondiabetic and obese type 2 diabetic subjects, while Cusi et al. [27]
reported no differences in insulin-stimulated PI3K, PKB and GS
activity using infusion rates between 120 and 300 mU m−2 min−1 in
patients with similar characteristics. Regarding the duration of the
clamp, previous studies have shown that post-receptor signaling
defects are observed as early as 2 h, 3 h, and even 30 min after insulin
infusion [6,25,26] and it has been shown that defective insulin-
stimulated (120 mU m−2 min−1) tyrosine phosphorylation was
detected after 30 min and sustained throughout 5 h [36].
Even if in vivo studies have been of great importance to determine
the metabolic changes that occur during insulin resistance and
diabetes, complementary in vitro techniques have likewise been
developed, providing a system which allow investigation of the
molecular mechanisms responsible for insulin resistance in muscle
and adipose tissue.
Performing biopsies before and after a clamp is instrumental to
pinpoint the alteration(s) of insulin signaling in patients with insulin
resistance and type 2 diabetes, as compared to healthy control
Fig. 2. Schematic diagram of signaling and metabolic events studies in human muscle from control subjects versus insulin resistant, obese or type 2 diabetic patients. The diagram
summarises studies from i) biopsy-derived primary human skeletal muscle cells, ii) needle biopsies, iii) muscle strips from abdominal surgeries. Red dots indicate the observation of
impairments versus control subjects, green dots indicate the absence of alteration in the biochemical/metabolic events studied, and red/green dots indicate either unchanged or
impaired versus control subjects.
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usedmay complicate the interpretations. These complications arise by
the location of the biopsy (mainly needle biopsy from vastus lateralis
obtained under local anaesthesia, or rectus abdominus strips obtained
during a surgical procedure), and whether the biopsy is directly
analysed or used to establish a biopsy-derived primary cell culture.
Overall, studies on muscle include muscle biopsies, muscle-strips in
culture and biopsy-derived primary muscle cells (Fig. 2).
In 1988 Dohm et al. elaborated an in vitro muscle preparation
derived from the rectus abdominus muscle that is structurally intact,
metabolically viable and responsive to insulin [37]. These muscle
strips were obtained through surgery and directly incubated ex-vivo.
This study model was used to study muscle ﬁbre strips from obese
patients with or without type 2 diabetes, showing a reduced insulin-
stimulated glucose transport rate in muscle strips derived from type 2
diabetic patients versus control subjects [38–40]. A cell system of
differentiated human myotubes, derived from human satellite cells
obtained from muscle biopsies, was subsequently developed that
display several features of mature skeletal muscles [41] and is a model
that has largely been used to study insulin resistance and diabetes
since it retains the diabetic phenotype [42–50].
Studies regarding insulin resistance and type 2 diabetes in adipose
tissue have also been performed, but to a lesser extent than in muscle
tissue. The techniques used for the study of adipose tissue is based on
isolated adipocytes from biopsy prepared by the collagenase method
developed by Rodbell [51] in rats and modiﬁed for use in human
adipocytes [23,52–62]. Other techniques that have been used include
whole adipose tissue explants [63].
An important issue regarding the adipose tissue is relative to the
time-spanbetween the obtention of the biopsy and the performance of
the experimental treatment(s) [64]. Analysis of adipocytes from lean
nondiabetic subjects 4 h after biopsy and after an overnight incubation
showed that ERK1/2 and p38 basal phosphorylationswere higher soon
after the explant, compared to an overnight incubation. Thus, when
ERK1/2 was analysed after 4 h it was strongly phosphorylated and did
not further respond to insulin, while – following overnight depho-sphorylation – it responded to insulin the following day. Therefore it
might be difﬁcult to compare studies in which adipose tissue biopsies
have been incubated for different time periods.
1.3. Alterations of insulin receptor functionality in insulin resistance
The advent of tools to determine the activatory status of the
insulin receptor allowed demonstration of its downregulation in
rodent models of insulin resistance and streptozotocin-induced
diabetes [65,66]. The ﬁrst attempt to evaluate the functionality of
insulin receptor in obese and obese type 2 diabetic subjects was
performed on partially puriﬁed insulin receptors – from abdominal
muscle biopsies – stimulated ex-vivo with insulin. 125I-insulin
binding to the receptor was impaired in both obese and obese type
2 diabetic patients, as was IR tyrosine kinase activity towards an
exogenous substrate; yet insulin-stimulated autophosphorylation
was comparable between control subjects, obese and type 2
diabetic patients [67]. Other studies, performed on partially puriﬁed
IR from isolated abdominal skeletal muscle strips from nonobese
type 2 diabetic patients, have also shown decreased 125I-insulin
binding and IR kinase activity as compared to control subjects [68].
A major advancement in the determination of the IR functionality
was set by the study of muscle biopsies taken before and after a
euglycaemic–hyperinsulinaemic clamp. Nolan et al. performed
dose-escalation (insulin from 0 to 1200 mU m−2 min−1) euglycae-
mic clamps on lean control subjects, obese nondiabetic and obese
type 2 diabetic patients and showed a modest impairment of
autophosphorylation of the IR [35]. A time course study performed
by the same group (with insulin infusions of 120 mU m−2 min−1) to
evaluate kinetic defects of insulin action demonstrated only modest
impairments in type 2 diabetes and obesity, thus suggesting the
existence of defects downstream of the activated IR. In adipocytes,
a reduction in 125I-insulin binding was observed in adipose tissue
from type 2 diabetic patients – irrespective of their degree of
obesity – and in insulin resistant subjects [52,56], as well as a
reduction of insulin-stimulated IR kinase activity in adipose tissue
Fig. 3. Schematic diagram of signaling and metabolic event studies in human adipose tissue ex-vivo from control subjects versus glucose intolerant, obese, insulin resistant or type 2
diabetic patients. Red dots indicate the observation of impairments versus control subjects, green dots indicate the absence of alteration in the biochemical/metabolic events studied,
and red/green spots indicate either unchanged or impaired versus control subjects.
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resulted in a reduction in insulin-stimulated lipogenesis [22] and
glucose transport in adipose tissue from type 2 diabetic patients
[55,57]. Importantly, kinetic defects in the activation of the IR that
were observed in adipocytes from obese and obese type 2 diabetic
patients [69], could be corrected by a 2-weeks intensive insulin
treatment [70]. In conclusion, a comparison of the activation
defects of the IR between muscle and adipocytes in insulin
resistant conditions indicates that the IR of adipocytes is more
subjected to dysregulation as compared to the muscle's receptor
(Figs. 2 and 3). It should be noted, however, that studies on muscle
IR activation kinetics compared biopsies collected before and after a
euglycaemic–insulinaemic clamp, while studies on adipose tissue
were performed on explants of fat tissue treated ex-vivo with
insulin which may explain the discrepancy in insulin responsive-
ness seen between skeletal muscle and fat.
Following these ﬁrst studies mainly biochemical in nature, a most
widely used approach to determine the degree of IR activation has
consisted in selective immunoprecipitation of the receptor followed
by determination of its tyrosine phosphorylation by western blotting.
This analysis has in most cases [30,31,39,71], but not all [72],
demonstrated a mild to non-existing impairment of IR activation on
samples ranging from biopsies and muscle strips to primary cultured
muscle cells.
1.4. Dysfunctions of IRS1/2-PI3K signaling
1.4.1. Defects of IRS1/2
The earlier observation that a phospho-protein with apparent
molecular weight of 180 kDa is a major target of the activated insulin
receptor led to the discovery of IRS1 and IRS2 [73]. Tyrosine
phosphorylated IRS proteins provide docking sites for SH2 domain
containing molecules, thus allowing the recruitment/activation of the
PI3K p85/p55/p50 adapter subunits and Grb2 (mediating the
transmission of the insulin signal) [73], and the tyrosine phosphatase
SHP2 which may be implicated in the extinction of the signal via IR
and IRS dephosphorylation [74]. To date, most of the studies on human
samples have investigated the alterations occurring on IRS1, but
recent research is also tackling the dysfunctions of IRS2 occurring
during insulin resistance.1.4.2. IRS1
Independent reports have shown that IRS1 tyrosine phosphor-
ylation is diminished in skeletal muscle of obese and type 2 diabetic
patients undergoing an hyperinsulinaemic clamp — leading to an
almost blunted interaction with p85 [27]; and in mounted muscle
strips from non-obese type 2 diabetic and morbidly obese non-
diabetic patients [39,72]. Similarly, in adipocytes derived from type
2 diabetic patients, reduced IRS1 tyrosine phosphorylation appeared
to be the ﬁrst upstream signaling step to be reduced [75]. A central
aspect of IRS proteins regulation during insulin signaling resides in
their serine/threonine phosphorylation, which can take place on
more than 20 identiﬁed phosphorylation sites leading to a complex
regulation of the IRS activatory state [76]. Initial studies in rodents
demonstrated that JNK-mediated phosphorylation of IRS1 Ser307
(i.e. Ser312 in human IRS1), a residue located close to the PTB
domain, promoted insulin resistance by impairing IRS1 binding to
the activated IR [77,78]. Other kinases have subsequently been
shown to target Ser312, including IKKβ [79] and mTOR [80]. Ser312
phosphorylation by JNK and IKKβ established a plausible link
between the instalment of insulin resistance and the activation of
pro-inﬂammatory pathways [81]. Likewise, the targeting of Ser312
by mTOR demonstrated the existence of a feedback controlling
mechanism within the insulin signaling cascade. Besides Ser312,
other serine/threonine phosphorylation sites endowed with poten-
tial regulatory roles are those located in proximity to the SH2
domain binding motifs YxxM. Among those residues is Ser636, that,
once phosphorylated by MAPK or mTOR, negatively modulates p85
PI3K binding to IRS1 [82,83]. In primary culture of myotubes from
type 2 diabetic patients, basal and insulin-stimulated levels of IRS1
phospho-Ser636 were increased [47]. Similarly, IRS1 Ser312 phos-
phorylation was increased in muscle biopsies from obese and type 2
diabetic patients [34]. Interestingly, while in muscle biopsies from
control subjects IRS1 Ser312 phosphorylation was modulated by
insulin infusion – increasing ≈3 fold – the increased basal
phosphorylation in obese and type 2 diabetic patients did not
allow for a further insulin-stimulated increase [34], suggesting that
either i) in the insulin resistant condition IRS1 Ser312 is stoichio-
metrically phosphorylated or ii) insulin signaling leading to IRS1
Ser312 phosphorylation is impaired. In keep with this second idea,
Danielsson et al. have demonstrated that – in cultured adipocytes
Fig. 4. Schematic diagram of IRS1, reporting newly discovered phosphorylation sites, the kinases mediating the site's phosphorylation, and the resulting effect caused on IRS1
functionality (red, inhibitory phosphorylation; green, activatory phosphorylation). On the bottom, previously identiﬁed phosphorylation sites, Ser312, Ser612 and Ser636, are
reported (reviewed in [76]). IRAK: IL-1 receptor associated kinase.
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Ser312 phosphorylation is attenuated, implying that augmented
IRS1 Ser312 following insulin stimulation is a physiologically normal
response, possibly implicated in the determination of the correct
amplitude and length of insulin action [75].
Further research in cell culture systems has allowed the determina-
tion of a large number of Ser/Thr phosphorylation sites on IRS1, the
responsible kinases and the impact of such phosphorylations on the
insulin signaling capacity [76]. Several new Ser/Thr phosphorylation
sitesmodulating IRS1 function have recently been reported [84–95], as
summarised in Fig. 4.While IRS1 Ser/Thr phosphorylationwas initially
viewed solely as a negative regulatory mechanism, it is now clear that
both positive and negative modulation of IRS1 function arise from
different phosphorylation patterns. Thus, the current understanding
on the modulation of IRS1 function by Ser/Thr phosphorylation in
human samples (either from control subjects or type 2 diabetic
patients) is rather limited inasmuch: i) only Ser312 and Ser636
phosphorylations have been studied in detail in muscle and adipose
tissue and ii) the standard methodological approach implies the use of
phosphospeciﬁc antibodies, with the associated speciﬁcity problems
and the difﬁculty to test a panel of antibodies directed to all the known
IRS1 phosphorylation sites within a single biological sample. These
experimental limitations will likely be overcome by the use of more
sensitive technologies. Recently, several groups have started to apply
mass spectrometry-based techniques to identify new aspects of IRS1
regulation through Ser/Thr phosphorylation. The advantages of mass
spectrometry-based techniques reside in the fact that the need for
isotopic/chemical labelling or phosphospeciﬁc antibodies is overcome
and low-abundance proteins, such as IRS1, are amenable to full
characterisation, since the overall Ser/Thr phosphorylation pattern can
be analysed within the same sample after tryptic digestion, with the
unphosphorylated peptides serving as endogenous internal standards
[96]. By this approach, Thr446 has been identiﬁed as a TNFα-induced
phosphorylation site, likely relaying a negative regulation [96], and
Ser570 has been identiﬁed as a PKC-ζ target involved in the negative
modulation of the insulin signal [92]. In addition, after overexpression
of human IRS1, Luo et al. simultaneously identiﬁed 12 phosphorylation
sites – among whom 10 were newly identiﬁed sites – and assigned to
Ser1223 a positive regulatory role [95]. While these studies dealt
primarily with the identiﬁcation of new phosphorylation sites on IRS1
in cell culture studies, a major advance has recently been provided by a
study by the group of Mandarino, in which insulin-induced IRS1 Ser
and Thr phosphorylations have been analysed in human percutaneous
biopsies from vastus lateralis muscle obtained before and after a 2-
hour euglycemic–hyperinsulinemic clamp [97]. This study allowed the
simultaneous identiﬁcation of 22 Ser/Thr phosphorylation sites and
the quantitative evaluation of Ser/Thr phosphorylation levels of 15
sites [97]. This study has provided, for the ﬁrst time, an overall picture
of the dynamic changes of IRS1 phosphorylation status after insulin
stimulation in healthy humans and set the technological standard forthe study of phosphorylation-dependent IRS protein dysfunctions in
insulin resistant subjects and type 2 diabetic patients.
1.4.3. IRS2
While studies on IRS1 regulation through Ser/Thr phosphorylation
mechanism ﬂourished, and studies on humans have started to deﬁne
the physiological response of IRS-1 to insulin, much less is known on
the modulatory processes regulating IRS2, although IRS1 and IRS2
appear to equally contribute to peripheral glucosemetabolism, at least
inmice [98]. In the vastmajority of the studies, PI3K activity associated
to IRS proteins has been monitored in IRS1 immunoprecipitates only
(Fig. 2). In the few studies in which PI3K activity associated to IRS1 or
IRS2 have been performed side by side [32,47,71], a decrease has been
observed in both IRS1- and IRS2-associated insulin-stimulated PI3K
activity in muscle biopsies from obese type 2 diabetic patients [32],
whereas a selective alteration of insulin-induced IRS1-associated PI3K
activity – after a 10-min stimulation with 100 nmol/l insulin – is
observed inmyotubes derived fromobese type 2 diabetic patients [47].
Another group has showed IRS2-associated defect, yet in a sustained
way from 3 to 60 min stimulation with 17 nmol/l insulin in myotubes
from insulin resistant obese individuals [71]. Whether alterations of
Ser/Thr phosphorylationpattern on IRS2 play a role in itsmodulation is
largely undetermined and should provide a fruitful ﬁeld of investiga-
tion, as IRS2 is known to be subjected to extensive phosphorylation
events that modulate its function both positively and negatively [99].
Although the IRS1 key regulatory residue Ser312 appears to be absent
in IRS2, sequence analysis revealed that IRS2 Thr348 could be the
homologous residue, being located within a potential JNK phosphor-
ylation site, and biochemical studies demonstrated that IRS2 Thr348
can be phosphorylated by JNK in vitro [100]. This biochemical
observation underscores a common theme in the negative regulation
of IRS1 and IRS2. Conversely, very recent data indicate that there is a
divergence in the regulation of IRS proteins through PKC-ζ-mediated
phosphorylation, with the IRS1 (and IRS3/4) being PKC-ζ targets, but
not IRS2 [101].1.4.4. PI3K
Insulin-induced PI3K action – leading to the production of PIP3 at
the plasma membrane catalysed by class Ι p110α/β PI3K catalytic
subunits – is the result of a complex interplay of many biochemical
events including:
- recruitment of PI3K at tyrosine phosphorylated IRS1/2
- relative contribution of the p110α and p110β catalytic isoforms,
which are combinatorially associated to the p85/55/50α and p85β
and p55γ adapter subunits
- modulation of the enzyme's action through interaction with RAS
- availability of the lipid substrate PtdIns(4,5)P2 at the plasma
membrane
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Although all these molecular events have been extensively
investigated (reviewed in [102–106]) and both PI3K and the PIP3
phosphatases are promising targets for therapeutic intervention to
improve insulin action [107,108], the current understanding of the
alterations of PI3K in insulin resistance and type 2 diabetes rests
essentially on in vitro PI3K assays performed on immunoprecipitates
to IRS1/2 or phosphotyrosines. While this procedure mirrors the
extent of interaction of PI3K to its upstream partners, it does not
provide information on all the other mechanisms implicated in the
regulation of intracellular PIP3 levels (such as the contribution of RAS
to PI3K activation and the activities of the phosphoinositol
phosphatases PTEN/SHIP2), thus leaving us in an uncertainty as to
what extent PI3K signaling is actually dysregulated in insulin
resistance and type 2 diabetes. Furthermore, the activities of class
ΙΙ and class ΙΙΙ PI3Ks should be taken into account to have an overall
picture of the contribution of PI3Ks in insulin signaling. Indeed, the
involvement of class II PI3Ks in insulin signaling, in cultured cells,
was demonstrated by the group of Shepherd [109] and the exact
mechanism of action has been elucidated more recently [110]. These
reports demonstrate the importance of PI3K-C2α, and its unique in
vivo lipid product, – PtdIns3P – as a lipid second messenger in insulin
action, in cell culture models, these ﬁndings suggest that dysregula-
tion of class ΙΙ and class ΙΙΙ PI3Ks may also occur in the insulin-
resistant state. A more reliable way to determine the extent of
PI3K-dependent defects would thus be the direct monitoring of the
PI3K lipid products PtdIns3P, PtdIns3,4P2 and PIP3.
While in vivo imaging techniques to visualise and quantify PIP3
in cell culture have been developed and used in L6 cells [111], to the
best of our knowledge such approaches have not yet been used on
human-derived skeletal muscle cells or adipocytes. Furthermore,
direct visualisation of PIP3 within an organism is as yet technically
out of reach. These intrinsic limitations in the study of PI3K action
in biopsy-derived samples can help explaining the current dis-
crepancies existing in the literature as to whether PI3K is impaired
or not in insulin resistance and type 2 diabetes. As an example,
several groups have reported defective PI3K activation (measured in
vitro as IRS1-associated activity) but unaltered PKB activation in
obese diabetic patients [6,30,32]. To fully understand this seemingly
paradoxical observation we would need to know whether phos-
phoinositide phosphatase activities of PTEN and SHIP2 are altered in
those subjects, as decreased activities could result in increased PIP3
levels in vivo, which may explain the retained PKB activation.
Furthermore, the contributions of class II and class III PI3Ks – that
are known to actively control insulin signaling [110,112] – to the
insulin resistant state have not yet been studied in humans.
1.5. Akt/PKB
The PI3K downstream target PKB, a serine/threonine kinase of
which α, β and γ isoforms have been reported, is a key enzyme
mediating the metabolic actions of insulin [113–115]. PKB activation
occurs through phosphorylation of Thr308 and Ser473, mediated by
PDK1 and the rictor–mTor complex respectively [9,116].
While PKBα is involved in the regulation of lipid metabolism
[117], the activation of glycogen synthesis in skeletal muscle [118]
and in insulin action in adipose cells [119]; it is PKBβ (the major
isoform expressed in skeletal muscle [120]) that is considered to be
the key isoform involved in insulin metabolic actions [118]. Finally,
although PKBγ is preferentially expressed in non-insulin dependent
tissues [121,122], reduced PKBγ activity in skeletal muscle of obese
and insulin resistant subjects has been reported [123].
Whether insulin-induced activation of PKB in insulin resistance
and type 2 diabetes is impaired is currently a debated matter. Somestudies reported signiﬁcant reductions of insulin-stimulated Ser473
or Thr308 phosphorylation in skeletal muscle of type 2 diabetic
patients [29,31,40], while others showed no alterations of phospho-
rylation or enzymatic activity of PKB between control subjects and
type 2 diabetic patients [27,31,32,124]. As previously mentioned, Kim
et al. [32] did not observe, in type 2 diabetic subjects, defects in PKBα
and β activities and phosphorylation, in spite of decreased insulin-
induced PI3K activation. This observation was subsequently con-
ﬁrmed by the observation of unaltered PKB phosphorylation in
muscle cultures and biopsies from control subjects and type 2
diabetic patients by employing phospho-speciﬁc antibodies [31,124].
On the other hand, Krook et al. [40] reported defective insulin-
induced activation of PKBα in isolated muscle strips from moderately
obese diabetic patients compared to BMI-matched control subjects. A
more recent and comprehensive study reported on the speciﬁc
activity of each PKB isoform, showing that PKBβ and γ (but not
PKBα) activities are diminished in skeletal muscle biopsies from
morbidly obese insulin resistant patients [123]. Additionally, our
laboratory recently demonstrated that isoform-speciﬁc alterations of
the PKB phosphorylation pattern occur in cultured primary myotubes
from type 2 diabetic patients in response to insulin, with defective
Ser473 phosphorylation on PKBβ and defective Thr308 phosphoryla-
tion on PKBα [29]. Furthermore, it was shown that PHLPP1, which is
able to dephosphorylate the Ser473 residue of PKBβ, is upregulated
in the muscle of type 2 diabetic patients compared to control
subjects [29].
Overall, the variability of PKB activation status must be viewed in
the light of the different patient cohorts characteristics used in each
study. As an example, Cozzone et al. [29] included overweight type 2
diabetic patients while Brozinick et al. included morbidly obese
insulin resistant patients [123]. In most studies biopsies are from
vastus lateralis [29,32,40,124] but in some instances strips from the
rectus abdominal muscle have been used [123].
Thus, unresolved issues on our current understanding of PKB
defects in insulin resistance derive from the fact that i) global PKB
phosphorylation is most often measured, disregarding isoform-
speciﬁcities; ii) samples are of different origin, i.e. biopsies, biopsy-
derived muscle strips or biopsy derived primary muscle cell culture
and, ﬁnally iii) cohort characteristics are rarely fully comparable
among different studies.
At present, a few studies have also interrogated PKB impairment in
adipocytes from type 2 diabetic subjects. With respect to this issue,
there is more consensus on the fact that PKB activation is impaired in
adipocytes derived from adipose tissue of type 2 diabetic patients
[125,126].
1.6. Atypical PKCs
The implication of aPKCs in insulin-stimulated GLUT4 transloca-
tion and glucose transport in muscle and adipose tissue has mainly
been shown by studies in animals (Reviewed in [127]). In human
isolated adipocytes, expression of PKC-ζ or PKC-λ/ι increased glucose
transport, while expression of kinase-inactive forms inhibited glucose
transport [128]. Numerous studies on animals report abnormalities in
the activation of aPKC in muscle and adipose tissue in insulin
resistance and type 2 diabetes (Reviewed in [127], and these
abnormalities are also found in humans.
In lean, nondiabetic human subjects, insulin stimulation leads to
a twofold increase in aPKC activity in muscle [6,14,30,34,71,129]
and adipose tissue [129], and a positive relationship was seen
between insulin-stimulated PKC- ζ/ λ activity and insulin-stimu-
lated glucose disposal rate [30]. The insulin stimulated activation
was diminished in myotubes from obese and/or obese type 2
diabetic patients [6,14,30,34,71,129] and adipocytes from obese
glucose intolerant subjects [129]. A further study using weight- and
age-matched nondiabetic and diabetic subjects, showing that
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diabetic group, allowed excluding obesity as the only reason
behind the abnormalities [6].
Also, PIP3 directly activates aPKCs in vitro, to a similar extent as does
insulin, inmuscle and adipose tissue fromnondiabetic patients [6,128],
while this activation is diminished in muscle samples from glucose
intolerant and type 2 diabetic patients [6] and myotubes and
adipocytes derived from obese glucose intolerant women [129]. This
abnormality in aPKC activity is sometimes accompanied by decreased
protein levels of PKC-ζ and/or PKC-λ/ι [6,30]. Even if there is no
evidence of direct interaction in vivo of PIP3 with the PH domain of
aPKCs, there are several studies showing that direct addition of PIP3 to
aPKC immunoprecipitates provokes insulin-like increases in aPKC
activities [6,14,129–131]. Alternatively, aPKCs activation may be
subsequent to PIP3-induced PLCγ activation [132,133].
Generally, all studies in humans, independently from the tissue
under study and the methodology employed, have shown impairment
of aPKC activity in obesity, insulin resistance and type 2 diabetes, as
summarised in Figs. 2 and 3.
1.7. MAPK signaling — ERK, JNK, p38
Besides the PI3K-PKB, insulin activation leads, through Grb2/Sos
and RAS, to the phosphorylation and activation of members of the
MAP kinase family, speciﬁcally ERK1/2, JNK and p38 MAPK, which
phosphorylate and control the activity of other downstream protein
kinases and transcription factors. However, not much is known about
whether theMAPK pathway is equally affected by insulin resistance as
the PI3K-PKB pathway.
The ﬁrst reports regarding MAP kinases showed that ERK1/2
phosphorylation in muscle biopsies was similar between control
subjects and type 2 diabetic patients [39] as was ERK1/2 phosphor-
ylation and activity and MEK1 activity [27]. These observation were
followed by the study of muscle biopsy-derived myotubes from
control subjects and type 2 diabetic patients, showing that the
phosphorylation levels of ERK1/2 were similar, both in the absence
and presence of insulin [124]. However, other studies have reported a
high basal phosphorylation state of ERK1/2 in muscle [34,47] and
adipose tissue [58,64] from type 2 diabetic patients compared to
control subjects. Some of the studies reported that the high levels of
ERK1/2 basal phosphorylation is accompanied by a lack of further
insulin stimulated phosphorylation in the type 2 diabetic patients
[34,58,64].
A few studies have also explored the dysregulations of other
members of the MAP kinase family. The level of JNK1 phosphorylation
has been reported to be elevated in the basal state in type 2 diabetic
patients compared to control subjects, both inmuscle [34] and adipose
tissue [58], with the high basal state possibly causing the lack of an
insulin-stimulated JNK activity. p38 MAPK phosphorylation was also
shown to be increased in basal state in muscle tissue from obese and
type 2 diabetic patients compared to control subjects [34,134], with
similar results observed in adipose tissue [58]. Upon insulin stimula-
tion, p38 phosphorylation increased in control subjects, while it
decreased in muscle tissue of type 2 diabetic patients [34,134], and
remained unchanged in adipose tissue from type 2 diabetic patients
[58].
The few studies available on the MAPK pathways in insulin
resistance indicate that this pathway is possibly altered, even if
discrepancies exist regarding this pathway. Similar effort needs to be
done regarding this pathway as for the PI3K-PKB pathway to elucidate
the alterations present during insulin resistance and type 2 diabetes.
2. Conclusions
During the past three decades, studies on themolecular alterations
of the insulin signaling cascade have allowed to establish a linkbetween the alterations of glucose metabolism observed in insulin
resistant and type 2 diabetic patients and the underlying molecular
defects in muscle and adipose tissue. While initial studies on the IR
suggested that its dysfunctionality could account for the insulin-
resistant phenotype, analysis of the intracellular components of the
insulin signaling pathway suggested that the defects mainly reside
intracellularly. As reviewed in this paper, and clearly pointed out in
Figs. 2 and 3, the only consensus reached by all studies to date is the
presence of alterations in aPKCs as well as inmetabolic responses such
as glucose disposal and transport. On the contrary, the occurrence of
defaults of upstream signaling components is more controversial,
with studies showing alterations in insulin resistance while others
ﬁnding no differences with respect to control subjects. This is mainly
apparent relatively to the defects observed at the levels of IRS proteins,
PI3K and PKB, as we discussed in detail in the relevant paragraphs.
The complexity of the insulin signaling pathway does not cease to
grow as new regulatory phosphorylation sites, proteins, protein
isoforms and interactions are reported. So far, the analysis of the insulin
signalingpathway in insulin resistancehas beenmainly focusedon IRS1/
2, PI3K and PKB. Further investigations on the phosphoinositide
phosphatases PTEN and SHIP2 may explain some of the discrepancies
reported between the PI3K and PKB activities. Therefore, the study of
PTEN and SHIP2 dysregulation in insulin resistance is warranted. Other
proteins participating in the signaling cascade might also need to be
taken into account, e.g. the newly discovered PKB isoform-speciﬁc
phosphatase PHLPP [135], of which some isoforms seem to be altered in
themuscle of type 2 diabetic patients [29]. Insulin also generates a pool
of the lipid PtdIns3P at the plasmamembrane, a lipidmessenger that has
been shown to be implicated in GLUT4 translocation [136]. While the
crucial role of PIP3 inmany signalingevents and intracellular functions is
well established, less is known about the role of other PI3K products,
even if it has been shown that PtdIns3P may play a dynamic role as a
second messenger, being synthesized de novo to transduce speciﬁc
signals downstream to cellular stimulation. Therefore, studies on the
implication of class ΙΙ and class ΙΙΙ PI3Ks, and their lipid products, in
insulin resistance are warranted.
The use of a mass spectrometry-based techniques for quantiﬁca-
tion of phosphorylation of IRS1 described by Yi et al. [96,97] is a
technique that allow the quantiﬁcation of several phosphorylation
sites simultaneously using the same sample, thereby reducing the
problem of sample availability. To date, this technique has only been
used to study phosphorylation of IRS1 protein in muscle samples from
healthy human muscle samples. Yet, with the availability of the
technology, it is likely that studies evaluating IRS1 and IRS2
phosphorylation in obese, insulin resistant and type 2 diabetic
patients will be performed in the near future. Similarly, it is likely
that mass spectrometry-based techniques will also be used to study
the phosphorylation patterns of other proteins of the signaling
cascade (e.g. PKB isoforms, aPKCs).
Since the clinical characteristics of lean and obese subjects as well
as insulin resistant and type 2 diabetic patients are different, the
subjects enrolled in the studies need to be well characterised and
study groups clearly deﬁned. As discussed earlier, differences in
experimental procedures (e.g. biopsies versus primary cell culture)
and duration and/or rate of insulin infusion needs to be considered
when trying to reach a consensus on defects in insulin signaling.
Furthermore, all studies reviewed in this article are based on studies in
small cohorts of insulin resistant, obese or type 2 diabetic patients,
with cohort sizes around 10 patients per group. The lack of bigger
cohort studies might also be one of the reasons for the reported
discrepancies. In future studies, to overcome the problem of patient
recruitment, which is not an easy task, one solution would be
multicentric studies, either national or international.
Our understanding of the defects of the insulin signaling cascade in
insulin resistance and type 2 diabetes will probably be fully attained in
the next few years as novel technologies are employed and more
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characteristics.
3. Current limitations and future prospects in the study of insulin
signaling in human muscle/adipose tissue
3.1. Limitations
Only a few IRS1 Ser/Thr phosphorylation regulatory sites are
studied within each independent investigation.
The knowledge of IRS2 regulation by Ser/Thr phosphorylation is
still very limited.
The extent of PI3K activation is only calculated on the basis of in
vitro PI3K activity associated to IRS1 and IRS2.
Only a few studies have addressed the isoform-speciﬁc deregula-
tion of PKB.
3.2. Future prospects
Use of mass-spectrometry techniques to simultaneously study
multiple Ser/Thr phosphorylation sites in IRS1 and IRS2.
Evaluation of PI3K lipid-kinase activity by measuring the actual
PIP3 production, in vivo.
Defects of class ΙΙ and ΙΙΙ PI3Ks need to be studied.
Study of PKB isoform speciﬁc deregulations.
More extensive study of MAPK pathway.
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